Sixto Giusti

Sixto Giusti

Auto-generated profile, based on publicly available information

Sixto Giusti

Department of Medicine University of Colorado School of Medicine Aurora Colorado USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
SGSixto Giusti
Sixto Giusti
YLYilu Lin
Yilu Lin
FSFolarin Sogbetun
Folarin Sogbetun
NNNazih Nakhoul
Nazih Nakhoul
SLShuqian Liu
Shuqian Liu
VBVecihi Batuman
Vecihi Batuman

11 November 2022 in Cureus
Verified
Journal Article
Open access
GDGina Defelice
Gina Defelice
SGSixto Giusti
Sixto Giusti
HJHoonbae Jeon
Hoonbae Jeon
MKMary Killackey
Mary Killackey
APAnil Paramesh
Anil Paramesh
AVAdarsh Vijay
Adarsh Vijay
Purpose: Kidney transplant recipients (KTRs) are at an increased risk of severe disease and death caused by coronavirus disease 2019 (COVID-19) infection. There is a paucity of information on the evolution of graft function among hospitalized KTRs who overcome the infection. Methods: The study included adult KTRs at a single transplant institute who were diagnosed with COVID-19 and needed hospitalization between March 15, 2020, and January 15, 2021. We analyzed patient demographics, comorbid risk factors, and inpatient clinical courses for patients who were able to recover from the infection. Kidney function was analyzed pre-infection, during initial hospitalization, and up to 12 months post-infection. Results: We identified 48 KTRs who were diagnosed with COVID-19 infection during the study period. Eighteen KTRs among these needed hospitalization for symptoms of fever and respiratory distress. Four patients died of COVID-19 infection-related complications and were excluded from the study. The 14 remaining patients in the study were predominantly of the Black race (85.7%), with a median time since transplant of four years. Of the patients, 64.3% developed acute kidney injury (AKI), with an average peak serum creatinine (sCr) of 2.6 mg/dl and a glomerular filtration rate (GFR) of 35. The mean sCr and GFR of the group were 2 mg/dl and 44 at baseline (prior to infection). This represented an increase in their sCr and GFR of 34% and 29%, respectively. The median follow-up post-infection was 14.5 months. sCr and GFR were 1.87 mg/dl and 47 at three to six months, and 1.89 mg/dl and 48 at nine to 12 months post-infection. New onset proteinuria was noted in five out of 14 patients (36%), with complete resolution of the same in all at three to six months follow-up. Of patients with AKI, 78% had complete recovery at three to six months follow-up. The mean baseline sCr and GFR of patients who had incomplete recovery was 2.35 and 31.5 with pre-existing proteinuria. Of our entire cohort, there was only one patient who experienced graft loss. This patient had a baseline sCr and GFR of 3.8 mg/dl and 22, existing proteinuria on urinalysis, and a history of biopsy-proven rejection. Conclusion: AKI is common among KTRs who are hospitalized with COVID-19 infection. Most of these recovered, although we noted that patients with baseline lower kidney function and existing proteinuria had a lower recovery rate.

19 September 2026 in The American Journal of Surgery
Verified
Journal Article
Closed access
HKHaaris Kadri
Haaris Kadri
RMRossana Maffei
Rossana Maffei
RDRyan Dang
Ryan Dang
KHKeith Hansen
Keith Hansen
DYDor Yoeli
Dor Yoeli
PAPhillipe Abreu
Phillipe Abreu

4 June 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SCShai Chazin
Shai Chazin
OSOsaid Saqqa
Osaid Saqqa
APAnil Paramesh
Anil Paramesh
SGSixto Giusti
Sixto Giusti
Click on the article title to read more.

16 December 2021 in Ochsner Journal
Verified
Journal Article
Open access
PDF file
SGSixto Giusti
Sixto Giusti
SCShai Chazin
Shai Chazin
PVPradeep Vaitla
Pradeep Vaitla
KAKofi Atiemo
Kofi Atiemo
MAMohammad Atari
Mohammad Atari
JGJorge Garces
Jorge Garces
Background: Kidney transplant recipients are at increased risk of severe disease and death caused by coronavirus disease 2019 (COVID-19) infection. The role of immunosuppressive medications in the clinical presentation, disease course, and outcomes is not well understood. Methods: We analyzed kidney transplant recipients diagnosed with COVID-19 and requiring hospitalization during the initial infection surge at 2 large transplant centers in New Orleans, Louisiana, between February 1, 2020 and April 30, 2020. Patient presentation, clinical course, kidney transplant function, and postdischarge details are included in this analysis. Results: Twenty-three kidney transplant recipients hospitalized with COVID-19 were included in the study. The majority of patients were Black (95.7%). Diabetes, hypertension, and obesity were present in more than 50% of the patients. The most common presenting symptom was fever, present in 52.2% of patients. All patients were managed with reduction in immunosuppression. Patients received azithromycin (60.9%), hydroxychloroquine (47.8%), remdesivir (8.7%), and intravenous methylprednisolone pulse (8.7%). The average length of stay was 4.5 days (range, 2-18 days). In this study population, 73.9% of the patients sustained acute kidney injury, with an average peak serum creatinine of 3.81 mg/dL. Twenty-six percent of the patients required renal replacement therapy. Seventy-seven percent of patients developed proteinuria (at least 1+ proteinuria on urinalysis). Of the patients in this population who required mechanical ventilation (39.1%), 77.8% died. Overall, 30.4% of patients died of COVID-19–related complications during admission. Of the 16 patients discharged, the average serum creatinine at discharge was 2.09 mg/dL compared with an average preadmission serum creatinine of 1.8 mg/dL. Conclusion: During the initial COVID-19 infection surge in New Orleans, we noted that kidney transplant recipients had initial symptoms similar to the general population. However, we recorded a higher incidence of acute kidney injury and death compared to nontransplant patients. Patients who required mechanical ventilation had a high mortality rate. Black patients are overrepresented in our study.

8 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
CNCamilla W. Nonterah
Camilla W. Nonterah
CSChristina Spivey
Christina Spivey
NHNicole Hayde
Nicole Hayde
MCMarie Chisholm-Burns
Marie Chisholm-Burns
SGSixto Giusti
Sixto Giusti
TLTzu-Hao Lee
Tzu-Hao Lee
Diversity, equity, inclusion, and belonging (DEIB) have implications for transplant access and outcomes. Inequities in transplantation have been identified over the years for minoritized groups based on race, ethnicity, sex, sexual orientation, gender identity, disability status, and other sociocultural identities. While DEIB initiatives have demonstrated success in improving transplant outcomes for some minoritized groups, many gaps still exist, and additional work is needed. Concerns about these practices have also been brought up, and they may create barriers to achieving DEIB goals. This underscores the importance of transplant organizational commitment to practices that uphold the values of DEIB, as such efforts are effective in reducing transplant inequities and fostering an inclusive community. In this viewpoint, we reviewed existing inequalities in transplant, importance of DEIB, common concerns of DEIB initiatives, and commitment of the American Society of Transplant to DEIB initiatives, including the foundation of Inclusion, Diversity, Equity, and Access to Life (IDEAL) committee. Recommendations for cultivating DEIB practices, as well as tips for managing backlash against DEIB initiatives, were also provided. All professionals within the field of transplantation should carefully consider these recommendations to help promote an inclusive community for patients, providers, and all key stakeholders.